NEW YORK, February 12, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Moments ago, Analysts Review released new research updates concerning several important developing situations including Alliqua (NASDAQ: ALQA), Almost Family (NASDAQ: AFAM), Alnylam Pharmaceuticals (NASDAQ: ALNY), Alphatec Holdings (NASDAQ: ATEC), and AMAG Pharmaceuticals (NASDAQ: AMAG). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
To access our full PDF reports on a complementary basis, please visit the links below.
--
Today's update concerns the following companies:
============
Full PDF Download Links (you may have to copy and paste the following links into your browser):
ALQA Research Report: ( http://get.analystsreview.com/pdf/?c=Alliqua&d=12-Feb-2015&s=ALQA ),
AFAM Research Report: ( http://get.analystsreview.com/pdf/?c=Almost%20Family&d=12-Feb-2015&s=AFAM ),
ALNY Research Report: ( http://get.analystsreview.com/pdf/?c=Alnylam%20Pharmaceuticals&d=12-Feb-2015&s=ALNY ),
ATEC Research Report: ( http://get.analystsreview.com/pdf/?c=Alphatec%20Holdings&d=12-Feb-2015&s=ATEC ),
AMAG Research Report: ( http://get.analystsreview.com/pdf/?c=AMAG%20Pharmaceuticals&d=12-Feb-2015&s=AMAG ).
============
--
Analyst Update: Acquisition Agreements, Quarterly Results, Clinical Trials, Appointments, and Business Updates
Reviewed by: Rohit Tuli, CFA®
U.S. stocks closed effectively flat in a relatively quiet trading session on Wednesday, February 11, as investors fixed their eyes on the developments of an emergency meeting of the eurozone countries to discuss Greece's finances. S&P 500 closed flat at 2,068.53, the Dow Jones Industrial Average edged lower 0.04% to 17,862.14 and Nasdaq Composite moved up 0.3% to close at 4,801.18. The European markets closed lower as investors awaited the outcome of the crucial meeting over financial aid to Greece, part of the several meetings scheduled over the coming days to decide the future of financial aid to Greece. The Asian markets ended mostly higher following a firm finish of global stocks on the preceding day, as well as driven by hopes for a deal between Greece and its international creditors.
Alliqua BioMedical, Inc. (Alliqua) has signed a definitive agreement to acquire Celleration, Inc., a privately held medical device company, for an initial purchase price of c.$30.4 million. The cash and stock transaction is expected to close in Q2 2015 and is subject to customary closing conditions, including Alliqua shareholder approval.
Almost Family Inc.'s (Almost Family) net service revenues for Q3 2014 increased to $123.7 million from $88.5 million in Q3 2013. Net income attributable to the Company for the quarter stood at $3.8 million, compared with $2.1 million in Q3 2013. Adjusted earnings from operations stood at $0.53 per diluted share as compared to $0.29 per diluted share in Q3 2013.
Alnylam Pharmaceuticals, Inc. (Alnylam Pharmaceuticals) has initiated a Phase 1/2 clinical trial with ALN-CC5, a subcutaneously administered investigational RNAi therapeutic targeting complement component C5 for the treatment of complement-mediated diseases.
Alphatec Holdings, Inc.'s (Alphatec Holdings), the parent Company of Alphatec Spine, Inc, announced that its Board of directors has appointed Tom C. Davis as a member of the Board with immediate effect. Mr. Davis' appointment expands the Alphatec Spine board to 10 directors.
AMAG Pharmaceuticals, Inc. (AMAG Pharmaceuticals) has provided its business update, including preliminary Q4 and 2014 financial results. For Q4 2014, the Company expects total revenues to be between $52.8 million and $54.5 million. AMAG Pharmaceuticals also presented its financial outlook for 2015.
--
About Analysts Review
At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.
--
Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
